GlassScriptPhysician profile
Stacy Allison Mandras
NPI 1407069818
$99,617.32
in general payments reported to CMS, 2019-2025
27 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $4,613 · 2021: $13K · 2022: $10K · 2023: $16K · 2024: $26K · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $15K · Food and Beverage: $5,632 · Travel and Lodging: $2,043 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,060.00 |
| Consulting Fee | $15,304.00 |
| Food and Beverage | $5,632.14 |
| Travel and Lodging | $2,043.13 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $64,422.92 | 2019-2024 | Remodulin, Tyvaso, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $20,365.73 | 2019-2025 | |
| Cvrx, INC. | $9,988.26 | 2021-2025 | Barostim Neo System |
| Abbott Laboratories | $1,665.68 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $799.99 | 2022-2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $791.96 | 2019-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $455.55 | 2022-2024 | |
| Impulse Dynamics (USA) INC. | $194.48 | 2023-2024 | Optimizer, Optimizer |
| Daxor Corporation | $144.50 | 2024 | Bva-100 |
| Medtronic Vascular, INC. | $131.02 | 2020 | |
| La Jolla Pharmaceutical Company | $123.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.82 | 2023 | Livtencity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.30 | 2020-2023 | Lifevest |
| Sandoz INC. | $70.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.85 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $32.08 | 2021 | |
| Edwards Lifesciences Corporation | $28.51 | 2025 | Evoque |
| American Regent | $24.93 | 2024 | Injectafer |
| Genentech USA, INC. | $24.26 | 2021 | |
| Briohealth Solutions, INC. | $21.57 | 2025 | Briovad |
| Mallinckrodt Enterprises LLC | $19.98 | 2019 | |
| Pfizer INC. | $17.66 | 2019 | |
| Gilead Sciences, INC. | $15.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.13 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Mandras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.